Hereditary ATTR Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Hereditary ATTR Amyloidosis Market Outlook

Thelansis’s “Hereditary ATTR Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary ATTR Amyloidosis   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hereditary ATTR Amyloidosis Overview

Hereditary ATTR Amyloidosis (hATTR) is a rare, autosomal dominant multisystem disorder caused by mutations in the transthyretin (TTR) gene, which lead to misfolding of the transthyretin protein and subsequent deposition of amyloid fibrils in various tissues. These deposits disrupt normal organ function, most commonly affecting the peripheral nerves, heart, gastrointestinal tract, and kidneys, though the central nervous system and eyes may also be involved in certain variants. Clinically, hATTR presents with a spectrum of symptoms depending on the mutation and organ involvement—ranging from progressive sensorimotor polyneuropathy and autonomic dysfunction to restrictive cardiomyopathy, arrhythmias, and heart failure. The disease often manifests in adulthood, with variable penetrance and age of onset, and may be misdiagnosed due to its overlap with other neuropathic or cardiac conditions.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hereditary ATTR Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034